XML 77 R80.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($) |  |  |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 01, 2019 | Oct. 01, 2018 | Jan. 01, 2018 | Oct. 01, 2017 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2017 | Jun. 30, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Mar. 01, 2018 | Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 58,000,000 |  |  |  |
Impairment of long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,000,000 |  |  |  |
Impairment of finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |
Impairment of indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 |  |  |  |
Carrying value of intangible assets, net |  |  |  |  | $ 10,201,000,000 |  |  |  | $ 12,001,000,000 |  |  |  |  |  | 10,201,000,000 | $ 12,001,000,000 |  |  |
Finite-lived intangible assets |  |  |  |  | 8,490,000,000 |  |  |  | 10,267,000,000 |  |  |  |  |  | 8,490,000,000 | 10,267,000,000 |  |  |
Net (loss) income attributable to Bausch Health Companies Inc. |  |  |  |  | $ (1,516,000,000) | $ (49,000,000) | $ (171,000,000) | $ (52,000,000) | $ (344,000,000) | $ (350,000,000) | $ (873,000,000) | $ (2,581,000,000) |  |  | (1,788,000,000) | (4,148,000,000) | $ 2,404,000,000 |  |
Decrease to earnings per share, basic and diluted (in dollars per share) |  |  |  |  | $ 4.30 | $ 0.14 | $ 0.49 | $ 0.15 | $ 0.98 | $ 1.00 | $ 2.49 | $ 7.36 |  |  |  |  |  |  |
Goodwill reallocated into (out of) |  |  |  |  | $ 13,126,000,000 |  |  |  | $ 13,142,000,000 |  |  |  |  |  | 13,126,000,000 | 13,142,000,000 | 15,593,000,000 |  | $ 15,794,000,000
Goodwill impairments | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 2,322,000,000 | 312,000,000 |  |
Accumulated goodwill impairment charges to date |  |  |  |  | 3,711,000,000 |  |  |  |  |  |  |  |  |  | 3,711,000,000 |  |  |  |
Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill reallocated into (out of) |  |  |  | $ 5,127,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total identifiable net assets |  |  |  | 10,660,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate purchase price, net |  |  |  | $ 13,404,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  | 2,213,000,000 |  |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  | 5.00% |  |  |  |  |
Dentistry Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  | $ 109,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 109,000,000 |  |  |
Reporting Units Excluding Dentistry |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting Units Excluding Ortho Dermatologics and Dentistry |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of fair value in excess of carrying value |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Baush and Lomb/International Segment | Scenario, Adjustment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill reallocated into (out of) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 264,000,000
Branded Rx Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  |  |  | $ 312,000,000 |  |  |  |  |  |
Branded Rx Segment | Scenario, Adjustment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill reallocated into (out of) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 115,000,000 |
Branded Rx Segment | Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  | $ 1,970,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Branded Rx Segment | Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  | $ 243,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bausch Lomb/International And U.S. Diversified Products Segments | Scenario, Adjustment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill reallocated into (out of) |  |  |  |  |  |  |  |  |  |  |  | $ (115,000,000) |  |  |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate | 9.80% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates | 1.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate | 9.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product rights/patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 55,000,000 | 95,000,000 |  |
Finite-lived intangible assets |  |  |  |  | 410,000,000 |  |  |  | 634,000,000 |  |  |  |  |  | $ 410,000,000 | $ 634,000,000 |  |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years |  |  |  |
Product rights/patents | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |
Product rights/patents | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |
Certain Product Brands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,618,000,000 |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years | 7 years |  |
Corporate brands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  |  |  |  | 592,000,000 |  |  |  | $ 663,000,000 |  |  |  |  |  | $ 592,000,000 | $ 663,000,000 |  |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 years |  |  |  |
Corporate brands | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20 years |  |  |  |
Corporate brands | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 years |  |  |  |
Held For Sale |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 | $ 114,000,000 |  |
Held For Sale | Sprout |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 351,000,000 |  |
Acquired IPR&D |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 28,000,000 | 3,000,000 |  |
Uceris |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 263,000,000 |  | 348,000,000 |  |  |
Carrying value of intangible assets, net |  |  |  |  | 47,000,000 |  |  |  |  |  |  |  |  |  | $ 47,000,000 |  |  |  |
Arestin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 132,000,000 |  |  |
Other Product Lines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 151,000,000 |  |
Salix | Corporate brands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 569,000,000 |  |
Estimated useful lives |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years | 17 years |  |
Xifaxan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Carrying value of intangible assets, net |  |  |  |  | $ 4,309,000,000 |  |  |  |  |  |  |  |  |  | 4,309,000,000 |  |  |  |
Xifaxan | Intangible Assets, Amortization Period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net (loss) income attributable to Bausch Health Companies Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 473,000,000 | $ 143,000,000 |  |  |
Decrease to earnings per share, basic and diluted (in dollars per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.34 | $ 0.41 |  |  |

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
Namespace Prefix: | bhc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Long-Term Growth Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestLongTermGrowthRate
Namespace Prefix: | bhc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256 + Details
Name: | us-gaap_EarningsPerShareBasicAndDiluted
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairedAccumulatedImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256 + Details
Name: | us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of fair value of reporting unit in excess of carrying amount. + References No definition available. + Details
Name: | us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_DentistryReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingDentistryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsAndDentistryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BrandedRxSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalAndU.S.DiversifiedProductsSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_CertainProductBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_SproutPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_UcerisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_ArestinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherProductLinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_SalixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_XifaxanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_IntangibleAssetsAmortizationPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |